From 1 - 10 / 129
  • Categories    

    Re-emergence of pertussis despite high vaccination coverage in western countries, results in increased risk for severe and even fatal pertussis among newborns. For this reason, late 2015 the Dutch Health Council (HC) advised to offer 3rd trimester pertussis vaccination to pregnant women. At the start of the maternal pertussis programme late 2019, the maternal Tdap was advised from 22w of gestation onwards. Preterms, accounting for 8% of newborns in the Netherlands, are at highest risk for severe pertussis leading to prolonged hospital and intensive care admissions and sometimes death. Recently, it has become evident that despite 3rd trimester vaccination, preterms remain at high risk because the vaccination is likely given too late for sufficient antibody transfer. For this vulnerable group 2nd trimester vaccination may offer better protection because of extended time for antibody transfer. To date, most countries recommend 3rd trimester vaccination to protect young, not yet (fully) vaccinated infants. Data from England show 91% effectiveness against infant pertussis after maternal Tetanus- diphtheria -acellular Pertussis (Tdap) vaccination in the 3rd trimester. Studies focussing on preterms and protection after maternal vaccination are scarce. Two observational studies reported on effectiveness and antibody levels in cord blood of 2nd trimester vaccination in term infants. While one study showed significantly higher antibody levels after 2nd trimester vaccination (13-25 gestational weeks; GW), another study showed decreased effectiveness of 2nd trimester (<27 GW) vaccination. Only one study concerned antibody transfer in preterms and reported higher antibody levels after 2nd (n=37) than after 3rd (n=48) trimester vaccination. Aiming to contribute to setting optimal vaccine strategy of maternal pertussis vaccination in the Netherlands and elsewhere and particular for the most vulnerable group of preterms, we propose a study that compares pertussis antibody levels in preterms and terms after 2nd trimester maternal vaccination. We can compare these to data we have on 3rd trimester Tdap in terms. In addition to adequate antibody levels, success of 2nd trimester vaccination depends on acceptance of this strategy by pregnant women and professionals. Our primary endpoint is IgG anti-pertussis toxin (Pt) antibody concentration in preterms and terms at 2m of age, Pt is considered the most relevant antibody for protection against clinical pertussis. Secondary endpoints are e.g. pertussis specific antibody concentrations in preterms and terms in cord blood and in women at delivery. Determinants of acceptance of 2nd trimester maternal vaccination are also a secondary endpoint. Antibody concentrations will be assessed in serum, using a fluorescent bead-based multiplex immunoassay, with required blood volume of minimal 100µl. For the survey on acceptance, we aim to have 4 groups of 100 women each, i.e. women who are pregnant for the 1st time, women who already gave birth and in both groups women with and without a known increased risk of preterm delivery. For the immunogenicity part, we aim to have at least 60 preterms and 60 terms, as this is, according to experts, the minimum number to enable good comparisons. Pregnant women will be offered 2nd trimester pertussis vaccination. Both among acceptors and non-acceptors acceptance of 2nd trimester vaccination will be assessed. Women are first asked to participate in the acceptance part after the 1st antenatal visit to a midwife or obstetrician. They fill in a questionnaire to assess behavioral determinants and beliefs that underlie acceptance of 2nd trimester maternal vaccination. Only after this consent, women will be asked to participate in the immunogenicity part. Hereby, women will receive Tdap after they have the 20w standard anomaly ultrasound scan (20-24 GW). Vaccinated women will be followed until delivery. All preterms and a random selection of 60 terms, all of vaccinated mothers, will be followed until 2m of age, i.e. just before start of the NIP. By including both women in primary and secondary antenatal care, we aim to enrich our study population with women who are at increased risk for preterm delivery, as these women are usually seen by an obstetrician. Data from our study will determine whether 2nd trimester Tdap leads to sufficient Pt antibodiy concentration in terms and preterms compared to 3rd trimester vaccination. Furthermore, we will have knowledge about obstacles for acceptance and can tailor information for all pregnant women to overcome these. Finally, given that in near future besides pertussis other maternal vaccines are likely to become available for prevention of severe disease in newborns (RSV, GBS), in particular in preterms, this study generates essential knowledge for future vaccine policy of maternal vaccines.

  • Categories    

    <p>Datasets used for the manuscript:&nbsp;<em>Long-term wastewater monitoring of SARS-CoV-2 viral loads and variants at the major international passenger hub Amsterdam Schiphol Airport: a valuable addition to COVID-19 surveillance</em></p> <p><em>pandemic_daily_passenger_counts.tsv</em>: An overview of daily passenger arrival&nbsp;counts at Amsterdam Schiphol Airport per continent of origin during the study period 16-02-2020 - 04-09-2022</p> <p><em>pre-pandemic_daily_passenger_averages.tsv:&nbsp;</em>An overview of mean daily passenger arrival counts at Amsterdam Schiphol Airport in the pre-pandemic period 2017-2019.</p> <p><em>viral_load_data.tsv:&nbsp;</em>Flow-corrected viral load (# particles per 24h) in samples taken at the wastewater treatment plant of Amsterdam Schiphol Airport.</p> <p><em>wastewater_variant_frequencies.tsv:&nbsp;</em>SARS-CoV-2 lineage estimates in samples&nbsp;taken at the wastewater treatment plant of Amsterdam Schiphol Airport, analyzed using whole-genome tiled amplicon sequencing.</p>

  • Categories  

    Genexpressie in bloed en lymfeknopen van muizen na infectie met RSV

  • Categories  

    Ammoniak (NH3) emissies naar lucht uit alle bronnen in 2014 in kg/km2 per jaar. Emissieregistratie 1990 - 2014. (vastgesteld 2016)

  • Categories  

    Geluidkaart 2016 voor Schiphol in het kader van de Regeling omgevingslawaai. De contouren op de kaart zijn gebaseerd op modelberekeningen van het NLR en geven inzicht in de geluidsbelasting in het voorgaande jaar (2016), hier het gebruiksjaar voor de luchthaven Schiphol dat liep van 1 november 2015 tot 1 november 2016. Over de kaart De kaart en de gegevens zijn afkomstig en eigendom van het ministerie van Infrastructuur & Milieu. De kaart bevat de geluidcontouren 48 en 58 dB Lden.

  • Categories  

    Genexpressie in longen van C3H en Hcb28 muizen na infectie met Bordetella pertussis

  • Categories  

    Genexpressie effecten in muizenlever bij cholestase door ciclosporine A blootstelling

  • Categories  

    genexpressie in rattenembryos na blootstelling aan diverse azolen

  • Categories    

    For English, see below Beschrijving bestand: Dit bestand bevat de volgende percentages: - (1) percentage deelnemers met klachten passend bij een acute luchtweginfectie in Infectieradar - (2) 7-daags gemiddelde van (1) naar rapportagedatum van de wekelijkse vragenlijst. Het bestand is als volgt opgebouwd: • Eén record per rapportagedatum Het bestand wordt een keer in de week geüpdatet, maar alleen gegevens van volledig afgeronde dagen worden weergegeven. Iedere week op dinsdag worden er zeven nieuwe dagen (dinsdag tot en met maandag) aan het bestand toegevoegd. Vanaf 6 september 2023 wordt dit bestand wekelijks op woensdag geüpdatet. De data wordt met terugwerkende kracht bijgewerkt voor de andere dagen. Beschrijving van de variabelen: Version: versienummer van de dataset. Wanneer de inhoud van de dataset structureel wordt gewijzigd (dus niet de dagelijkse update of een correctie op record niveau), zal het versienummer aangepast worden (+1) en ook de corresponderende metadata in RIVMdata (data.rivm.nl). Date_of_report: Datum en tijd waarop het databestand is aangemaakt door het RIVM. Date_of_statistics: Datum waarop de wekelijkse vragenlijst is ingestuurd. Perc_ari_symptoms: Percentage deelnemers in Infectieradar dat in de week voor de [Date_of_statistics] klachten heeft gerapporteerd passend bij een acute luchtweginfectie. Acute luchtweginfectie klachten zijn hoesten, keelpijn, kortademig, loopneus of verstopte neus. MA_perc_ari_symptoms: Het zevendaags lopende gemiddelde (moving average/MA) van [Perc_ari_symptoms]. Dit gemiddelde wordt op de middelste dag weergegeven. Voor de eerste 3 en de laatste 3 dagen in de dataset is deze waarde leeg, omdat deze dagen niet in het midden van een 7 daagse periode liggen. Vanaf 24 november 2022 zijn de analyses van Infectieradar met terugwerkende kracht aangepast. Hierdoor zijn er minimale verschillen in de resultaten die voor deze datum gepubliceerd waren. -------------------------------------------------------------------------------- Acute respiratory Infections Percentage of participants with symptoms consistent with an acute respiratory infection in Infectieradar per reporting date File description: This file contains the following percentages: - (1) percentage of participants with symptoms consistent with an acute respiratory infection in Infectieradar - (2) 7-day average of (1) per reporting date of the weekly questionnaire. The file is structured as follows: • One record per reporting date The file is updated once a week, but only data from fully completed days is displayed. Every week on Tuesday, seven new days (Tuesday through Monday) are added to the file. From September 6, 2023, this file will be updated weekly on Wednesdays. The data is retroactively updated for the other days. Description of the variables: Version: version number of the dataset. When the content of the dataset is structurally changed (so not the daily update or a correction at record level), the version number will be adjusted (+1) and also the corresponding metadata in RIVMdata (data.rivm.nl). Date_of_report: Date and time on which the data file was created by the RIVM. Date_of_statistics: Date on which the weekly questionnaire was submitted. Perc_ari_symptoms: Percentage of participants in Infectieradar who reported symptoms consistent with an acute respiratory infection in the week before the [Date_of_statistics]. Acute respiratory complaints are cough, sore throat, shortness of breath, dyspnea. MA_perc_ari_symptoms: The 7-day moving average (MA) of [Perc_ari_symptoms]. This average is shown on the middle day. For the first 3 and last 3 days in the dataset, this value is empty, because these days are not in the middle of a 7-day period. From November 24, 2022, the analyzes of Infectieradar have been adjusted retroactively. As a result, there are minimal differences in the results published before this date.

  • Categories  

    Methaan (CH4) emissies naar lucht uit alle bronnen in 2014 in kg per jaar. Emissieregistratie 1990 - 2014 (vastgesteld 2016)